The pain relieving patch Nanopatch

Equipment for drug delivery into the body by nanotechnology is developed by experts from the University of Queensland (Australia), which is about to be sold to the market by Vaxxas, promising to end the fear of vaccination and injections of the majority of the population. New technology will help reduce the risk of accidents involving needles (causing about 1.3 million deaths a year).

The nanopatch consists of more than 20,000 microscopic needles pressed on a piece of silicon 1cm ^{2 in} size. These needles are so small that the nervous system cannot detect them through the skin, so users don't feel pain. They can penetrate deep under the skin, and because vaccines or drugs cover the needles, they are directed to immune cells under the skin. Experts say the immune cells under the skin will allow the vaccine to develop a stronger response than the vaccine injected in the normal way.

At the same time, stronger cells kill the biological material of the vaccine - the virus's antigens. These cells then move to the lymph nodes to activate immune cells to create a lasting immune effect.

One of the biggest benefits of the Nanopatch is that it does not necessarily use liquid vaccines. Because it uses biological materials, it is completely dry and does not need to be stored in a cold environment, greatly saving the effort and cost of preserving the vaccine. Moreover, the Nanopatch also reduces the cost of vaccination. Dr Mark Kendall said that because the technology requires little antigens, "a $ 10 vaccine could be reduced to 10 cents - which is very important for developing countries." growing ".